- Home
- ELAB vs BFRI Comparison
ELAB vs BFRI Comparison
Compare ELAB & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- BFRI
- Stock Information
- Founded
- ELAB 2020
- BFRI 1997
- Country
- ELAB United States
- BFRI United States
- Employees
- ELAB N/A
- BFRI N/A
- Industry
- ELAB
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- BFRI Health Care
- Exchange
- ELAB Nasdaq
- BFRI Nasdaq
- Market Cap
- ELAB 6.6M
- BFRI 6.2M
- IPO Year
- ELAB 2023
- BFRI 2021
- Fundamental
- Price
- ELAB $1.65
- BFRI $1.11
- Analyst Decision
- ELAB
- BFRI Strong Buy
- Analyst Count
- ELAB 0
- BFRI 1
- Target Price
- ELAB N/A
- BFRI $7.00
- AVG Volume (30 Days)
- ELAB 4.6M
- BFRI 158.3K
- Earning Date
- ELAB 03-28-2025
- BFRI 03-14-2025
- Dividend Yield
- ELAB N/A
- BFRI N/A
- EPS Growth
- ELAB N/A
- BFRI N/A
- EPS
- ELAB N/A
- BFRI N/A
- Revenue
- ELAB $2,446,161.00
- BFRI $35,358,000.00
- Revenue This Year
- ELAB N/A
- BFRI $17.69
- Revenue Next Year
- ELAB N/A
- BFRI $19.71
- P/E Ratio
- ELAB N/A
- BFRI N/A
- Revenue Growth
- ELAB 112.17
- BFRI 5.17
- 52 Week Low
- ELAB $1.60
- BFRI $0.65
- 52 Week High
- ELAB $166.00
- BFRI $2.43
- Technical
- Relative Strength Index (RSI)
- ELAB 39.27
- BFRI 49.87
- Support Level
- ELAB $1.60
- BFRI $1.06
- Resistance Level
- ELAB $1.80
- BFRI $1.16
- Average True Range (ATR)
- ELAB 0.11
- BFRI 0.07
- MACD
- ELAB 0.04
- BFRI -0.00
- Stochastic Oscillator
- ELAB 15.66
- BFRI 55.00
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.